QuintilesIMS

QuintilesIMS
Name	QuintilesIMS
Type	Private
Industry	Pharmaceutical services
Founded	1982 (Quintiles), 1954 (IMS Health)
Fate	Rebranded as IQVIA in 2017
Headquarters	Durham, North Carolina; Parsippany, New Jersey
Products	Clinical research, consulting, data analytics
Num employees	~60,000 (2016)

QuintilesIMS QuintilesIMS was a multinational provider of biopharmaceutical development and commercial outsourcing services formed by the merger of Quintiles and IMS Health. The company combined clinical research organization operations, real-world evidence analytics, and healthcare information assets to serve pharmaceutical company clients, biotechnology company partners, and medical device manufacturers. QuintilesIMS operated globally until a corporate rebranding created a new entity serving healthcare markets.

History

QuintilesIMS traces lineage to the founding of Quintiles in 1982 and IMS Health in 1954; Quintiles was established by Dennis Gillings as a contract research organization in Research Triangle Park, North Carolina, while IMS Health evolved from the work of Molin and Company and market measurement in Philadelphia. Throughout the late 20th century, Quintiles expanded through partnerships with GlaxoSmithKline, Pfizer, Roche, and Eli Lilly to deliver clinical trial management and pharmacovigilance, while IMS Health amassed prescription and sales datasets used by Novartis, Sanofi, AstraZeneca, and Merck. In the 2000s and 2010s both companies pursued international expansion into markets such as China, India, Brazil, Russia, and South Africa and engaged with regulators like the Food and Drug Administration and the European Medicines Agency. The October 2016 announcement of a merger between Quintiles and IMS Health followed strategic trends exemplified by prior consolidations in the sector, including deals involving LabCorp, PAREXEL, ICON plc, and Charles River Laboratories.

Corporate structure and leadership

Prior to rebranding, QuintilesIMS maintained dual headquarters and a matrix structure with business units for clinical services, commercial services, and technology. Leadership included executives with backgrounds at GlaxoSmithKline, Eli Lilly, Bain & Company, and McKinsey & Company; boards and executive teams interfaced with major investors including private equity firms such as TPG Capital and Warburg Pincus. The company reported to regulatory bodies including the Securities and Exchange Commission for U.S. filings when public entities were in its ownership chain and coordinated governance across jurisdictions such as United Kingdom, Germany, and Japan.

Services and products

QuintilesIMS offered a portfolio spanning clinical trial management, site monitoring, therapeutic expertise, safety surveillance, market access consulting, and data licensing. Core offerings incorporated electronic health record-linked datasets, claims analytics, patient-reported outcomes, and marketing intelligence used by clients like Johnson & Johnson, Bristol-Myers Squibb, AbbVie, Bayer, and Takeda. Technology platforms integrated solutions developed alongside vendors in Silicon Valley, partners in Israel's healthtech sector, and research collaborations with institutions such as Johns Hopkins University, Harvard Medical School, and Imperial College London. Services supported regulatory submissions to agencies including the European Medicines Agency and the Pharmaceuticals and Medical Devices Agency.

Mergers, acquisitions and rebranding

The merger of Quintiles and IMS Health followed a history of acquisitions: Quintiles had acquired companies such as Kinapse and regional CROs, while IMS Health purchased data and analytics firms to enhance its market intelligence. The 2016 combination paralleled consolidation seen in deals like Pfizer–Wyeth, Abbott Laboratories acquisitions, and the expansion strategies of Oracle into life sciences. In 2017 the combined company announced a corporate name change to IQVIA, aligning branding with a unified corporate strategy and echoing rebrandings by firms such as Aetna and Kingfisher in other sectors.

Global operations and locations

QuintilesIMS operated across North America, Europe, Asia-Pacific, Latin America, and the Middle East with major offices in Durham (North Carolina), Parsippany (New Jersey), London, Basel, Tokyo, Shanghai, Mumbai, and São Paulo. The company ran clinical trial sites and data centers in regions governed by laws such as the Health Insurance Portability and Accountability Act and data protection regimes in European Union member states, and engaged local regulators like China Food and Drug Administration counterparts. Global logistics and site networks were comparable to those maintained by Medtronic and GE Healthcare in scope.

Financial performance and market position

Before rebranding, QuintilesIMS reported revenues positioning it among the largest vendors in the CRO and healthcare information markets, competing with IQVIA’s antecedents, PAREXEL International, ICON plc, LabCorp, and Syneos Health. Financial metrics reflected recurring revenues from long-term contracts with multinational clients such as GlaxoSmithKline, Pfizer, and Roche and investments from private equity and public markets similar to transactions involving KKR and Blackstone. Market analyses by industry watchers compared its valuation to peers in S&P 500-adjacent sectors and to healthcare IT firms like Cerner and McKesson.

Controversies and regulatory issues

QuintilesIMS faced scrutiny over data privacy, pricing of aggregated datasets, and relationships with pharmaceutical clients, paralleling controversies that touched Cambridge Analytica and data practices criticized in inquiries in United States Congress hearings. Regulatory interactions included reviews by agencies such as the Federal Trade Commission when prior acquisitions raised competition questions, and compliance audits tied to Good Clinical Practice and International Council for Harmonisation guidelines. Legal and ethical debates involved stakeholders from Physicians for Human Rights, World Health Organization, and academic critics at Harvard University and University of Oxford over access to anonymized health data and influence on prescribing patterns.

Category:Contract research organizations